Allogeneic T Cell Therapies Market Report, 2024-2028 & 2033 - Valued at $1.16 Billion in 2024, the Industry is Forecast to Generate Revenues of $1.69 Billion by 2028
December 12, 2024 05:38 ET
|
Research and Markets
Dublin, Dec. 12, 2024 (GLOBE NEWSWIRE) -- The "Allogeneic T Cell Therapies Market, 2024-2028 & 2033" report has been added to ResearchAndMarkets.com's offering. The allogeneic T cell...
CAR T-cell Therapy Strategic Business Research Report 2024: Global Market to Reach $10.8 Billion by 2030 - Expanding Clinical Applications Beyond Blood Cancers Expands Opportunities
December 02, 2024 06:31 ET
|
Research and Markets
Dublin, Dec. 02, 2024 (GLOBE NEWSWIRE) -- The "CAR T-cell Therapy - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for CAR T-cell...
Gene Editing Market Forecast Report 2024, with Profiles of Merck, GenScript, Revvity, Lonza, Precision BioSciences, Cellectis, AMSBIO, Synthego, Takara Bio, Bio-Techne, Reprocell and More
November 29, 2024 04:43 ET
|
Research and Markets
Dublin, Nov. 29, 2024 (GLOBE NEWSWIRE) -- The "Gene Editing Market by Product (Kits, Reagents, Libraries, Software), Services (GRNA Synthesis & Vector Construction), Technique, Technology...
Cell and Gene Therapy Tools and Reagents Market Report 2024 - Driving Medical Advances: Cell and Gene Therapy Tools Market to Hit $16.7 Billion by 2029
November 29, 2024 04:24 ET
|
Research and Markets
Dublin, Nov. 29, 2024 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Tools and Reagents Market" report has been added to ResearchAndMarkets.com's offering.The Cell and Gene Therapy Tools and...
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
November 15, 2024 11:02 ET
|
Barinthus Biotherapeutics
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
November 15, 2024 11:01 ET
|
Barinthus Biotherapeutics
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with
Cell and Gene Therapy CRO Market Research Trends and Global Forecasts, 2024-2035: Over 105 CROs Drive Innovation, with 80% Ensuring Comprehensive Support from R&D to Clinical Trials
November 04, 2024 05:40 ET
|
Research and Markets
Dublin, Nov. 04, 2024 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy CRO Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Cell Therapy, Type of Genetic Modification,...
Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences
October 31, 2024 08:00 ET
|
Barinthus Biotherapeutics
Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences
Tevogen Bio Provides Additional Guidance on Introduction of T Cell Therapy for Oncology and Specialty Care Therapeutic Areas
October 25, 2024 17:34 ET
|
Tevogen Bio Inc
WARREN, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...
Spain CAR-T Cell Therapy Market Forecast to 2029, Featuring Strategic Profiles of Gilead Sciences, Novartis Int'l, Bristol Myers Squibb, AbbVie, AMGEN, Pfizer, Merck & Co, Johnson & Johnson
October 23, 2024 12:03 ET
|
Research and Markets
Dublin, Oct. 23, 2024 (GLOBE NEWSWIRE) -- The "Spain CAR-T Cell Therapy Market, By Region, Competition, Forecast & Opportunities, 2019-2029F" report has been added to ResearchAndMarkets.com's...